



New York State Medicaid Preferred Drug Program 2019 Therapeutic Class Review

The New York Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2019 as they pertain to the fee-for-service (FFS) Preferred Drug Program (PDP). For the therapeutic classes (provided below), new relevant clinical and/or financial information is known to exist. DUR Board meeting agendas for 2019 are posted to the Department of Health (DoH) web-site thirty days prior to the meeting date.

Therapeutic Category	Therapeutic Class	Previous Review Date
Anti-infectives	Tetracyclines	June 27, 2013
Central Nervous System	Anticonvulsants - other	April 27, 2017
	Antimigraine Agents - other	Initial Review
	CNS Stimulants	September 20, 2018
	Movement Disorder Agents	Initial Review
	Multiple Sclerosis Agents	April 27, 2017
Endocrine and Metabolic Agents	Growth Hormones	April 24, 2014
Hematologic Agents	Colony Stimulating Factors	Initial Review
	Erythropoiesis Stimulating Agents	April 22, 2015
Immunologic Agents	Immunosuppressives - oral	Initial Review
Renal and Genitourinary	Antihyperuricemics/Xanthine Oxidase Inhibitors	April 29, 2010
Respiratory	Anticholinergic/COPD Agents	September 20, 2018

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DoH proposes no changes to the Preferred Drug List (PDL). If interested parties have new relevant clinical information, please submit to the Medicaid Pharmacy Department (dur@health.ny.gov) in a timely manner. The DoH will consider any new relevant clinical information provided when developing future DUR Board meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on prior meeting agendas which may be viewed at http://www.health.ny.gov/health_care/medicaid/program/dur

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials. Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available. Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to dur@health.ny.gov (please reference DUR Board PDP Review).

Please continue to monitor the DoH web-site for DUR Board meeting schedules and agendas at http://www.health.ny.gov/health_care/medicaid/program/dur